Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thyroid hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: A Phase III, Prospective, Placebo-Controlled, Double-Blinded, Randomized, Multi-Center Study to Determine the Safety and Efficacy of Calcijex® (Calcitriol Injection) in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric End Stage Renal Disease Patients on Hemodialysis
    Active substance: CALCITRIOL
    Study summary document link (including results): Calcitriol-1999007.pdf
    View full study record
    Document reference: 47097
    Study title: Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ, Elashoff RM, Jüppner H. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol. 2005 Aug; 16(8):2501-8. Epub 2005 Jun 8. Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ, Elashoff RM, Jüppner H. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol. 2005 Aug; 16(8):2501-8. Epub 2005 Jun 8.
    Active substance: CALCIUM CARBONATE
    Study summary document link (including results):
    View full study record
    Document reference: 23163
    Study title: Prevalence of goitre and hypothyroidism in Southern Tanzania: Effect of iodised oil on thyroid hormone deficiency.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39970
    Study title: Effect of oral iodized oil on thyroid size and thyroid hormone metabolism in children with concurrent selenium and iodine deficiency. ; Zimmermann-M-B. European Journal of Clinical Nutrition, 2000, Vol /Iss/Pg. 54/3 (209-213)Effect of oral iodized oil on thyroid size and thyroid hormone metabolism in children with concurrent selenium and iodine deficiency. ; Zimmermann-M-B. European Journal of Clinical Nutrition, 2000, Vol /Iss/Pg. 54/3 (209-213)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30234
    Study title: Prevalence of goitre and hypothyroidism in Southern Tanzania: Effect of iodised oil on thyroid hormone deficiency. ; Wachter-W. Journal of Epidemiology and Community Health, 1986, Vol/Iss/Pg. 40/1 (86-91)Prevalence of goitre and hypothyroidism in Southern Tanzania: Effect of iodised oil on thyroid hormone deficiency. ; Wachter-W. Journal of Epidemiology and Community Health, 1986, Vol/Iss/Pg. 40/1 (86-91)
    Active substance: IODINE
    Study summary document link (including results):
    View full study record
    Document reference: 30311
    Study title: Influence of timing and dose of thyroid hormone replacement on development in infants with congenital hypothyroidismJ Pediatr 2000; 136: 292-297 Bongers-Schokking JJ., 2000
    Active substance: LEVOTHYROXINE
    Study summary document link (including results): 20140709_Art 45 Studies.xlsx
    View full study record
    Document reference: 48982
    Study title: A Phase IV, Double-Blind, Placebo-Controlled, Multi-Center Study to Determine the Safety and Effectiveness of Zemplar in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric End Stage Renal Disease Subjects on Hemodialysis
    Active substance: PARICALCITOL
    Study summary document link (including results): Paricalcitol-2001022.pdf
    View full study record
    Document reference: 45819
    Study title: Colls F. et.al, Changes in plasma thyroid hormones levels after a single dose of triiodothyronine in prmature infants of less than 30 weeks gestational age, Eur. J. Endocrinology 143, 733-740, 2000
    Active substance: LIOTHYRONINE
    Study summary document link (including results):
    View full study record
    Document reference: 47215
    Study title: Aktas A, Elahi N. Bone scan findings in patients with chronic renal failure having symptoms related to bone: correlation with parathyroid hormone levels. Transplant Proc. 1999 Dec;31(8):3309-11. No abstract available. Aktas A, Elahi N. Bone scan findings in patients with chronic renal failure having symptoms related to bone: correlation with parathyroid hormone levels. Transplant Proc. 1999 Dec;31(8):3309-11. No abstract available.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43498
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 26 02:19:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA